Journal article icon

Journal article

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

Abstract:

BACKGROUND: Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after resection. METHODS: Microarrays from 434 patients randomized to chemotherapy in the ESPAC-3 trial (plus controls from ESPAC-1/3) were stained with the 10D7G2 anti-hENT1 antibody. Patients were classified as having high hENT1 expression if the mean H score for their cores was above the overall median H score (48). High and ...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1093/jnci/djt347

Authors


Greenhalf, W More by this author
Neoptolemos, JP More by this author
Palmer, DH More by this author
Expand authors...
Journal:
Journal of the National Cancer Institute
Volume:
106
Issue:
1
Pages:
djt347
Publication date:
2014-01-05
DOI:
EISSN:
1460-2105
ISSN:
0027-8874
URN:
uuid:df7e4000-d31f-45fa-bb4a-65aaaf2813b5
Source identifiers:
441738
Local pid:
pubs:441738

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP